RxDoctor Payments Data

Hae Young Song, MD

Allergy & Immunology · Yorba Linda, CANPI 1831181569

Payments from drug & device makers

$7,296in general payments, 2019–2025

Across 347 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • GSK$971
  • Novartis$543
  • Pfizer$502
  • CSL Behring$480
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$7,12398%
  • Education$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,296 in reported general payments places this provider in the 65th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$27,243
Medicare patients
84
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab12$31,075
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$27,527
Breo ElliptaFluticasone/Vilanterol17$9,586
DuleraMometasone/Formoterol13$5,370
Qvar RedihalerBeclomethasone Dipropionate18$4,974
Arnuity ElliptaFluticasone Furoate15$3,126
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,832
Azelastine Hcl25$788
Fluticasone Propionate35$724
Albuterol Sulfate HfaAlbuterol Sulfate21$548
Levocetirizine Dihydrochloride13$365
Ipratropium Bromide12$355
Montelukast Sodium20$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$971$40,24055 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$214$4,97418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →